市場調査レポート

商品コード

1566307

悪性胸膜中皮腫の世界市場：薬剤タイプ別、投与経路別、流通経路別、地域別、国別の分析、市場考察、予測

Global Malignant Pleural Mesothelioma Market : Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast

出版日: 2024年10月01日
発行: Azoth Analytics
ページ情報: 英文 259 Pages
納期: 即納可能

価格

PDF (Single User License)

USD 2,450 352,947円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 2,950 424,977円

レポートPDFを同一企業内の全員にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の悪性胸膜中皮腫の市場規模は、2020年～2023年にCAGRで4.98%の成長を示し、2023年に6億4,899万米ドルとなり、2030年に10億4,569万米ドルに達すると予測されます。

世界の悪性胸膜中皮腫市場は、複数の主な要因によって予測期間に大きな成長を示すと予測されています。もっとも顕著な促進要因の1つは、特に歴史的にアスベストが使用されてきた地域におけるアスベスト関連疾患の罹患率の増加です。世界保健機関（WHO）によると、アスベストは依然として中皮腫の主な原因であり、特定の地域における持続的なリスクが明示されています。

免疫療法や遺伝子治療のような革新的な治療法も、患者に治療成績の改善と新たな希望を提供することで市場拡大に寄与しています。こうした新治療法は、特に先進地域で支持を集めており、先進の医療インフラが最先端治療の採用を支えています。啓蒙活動の高まりは早期発見率の向上に寄与し、これらの治療法の有効性をさらに高めています。

さらに、新興市場における医療インフラの拡大により、先進の診断・治療オプションへのアクセスが拡大し、市場成長に拍車をかけています。

当レポートでは、世界の悪性胸膜中皮腫市場について調査し、市場規模と予測、地域とセグメントの分析、主な動向と機会などの情報を提供しています。

悪性胸膜中皮腫市場に対するマクロ経済要因の影響の分析
アスベスト輸出上位者：国別（2021年）
アスベスト輸入上位者：国別（2021年）
中皮腫の有病率と罹患率（2018年～2021年）
世界の悪性胸膜中皮腫市場：ダッシュボード
世界の悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
世界の悪性胸膜中皮腫市場：市場金額の評価
世界の悪性胸膜中皮腫市場セグメント：薬剤タイプ別
- 世界の悪性胸膜中皮腫市場：薬剤タイプ別、概要
- 世界の悪性胸膜中皮腫市場の魅力指数：薬剤タイプ別
- 世界の悪性胸膜中皮腫の市場規模：ペメトレキセド、併用（2020年～2030年）
- 世界の悪性胸膜中皮腫の市場規模：シスプラチン（2020年～2030年）
- 世界の悪性胸膜中皮腫の市場規模：カルボプラチン（2020年～2030年）
- 世界の悪性胸膜中皮腫の市場規模：ゲムシタビン（2020年～2030年）
- 世界の悪性胸膜中皮腫の市場規模：ビノレルビン（2020年～2030年）
- 世界の悪性胸膜中皮腫の市場規模：その他の薬剤タイプ（2020年～2030年）
世界の悪性胸膜中皮腫市場セグメント：投与経路別
- 世界の悪性胸膜中皮腫の市場：投与経路別、概要
- 世界の悪性胸膜中皮腫市場の魅力指数：投与経路別
- 世界の悪性胸膜中皮腫の市場規模：経口（2020年～2030年）
- 世界の悪性胸膜中皮腫の市場規模：非経口（2020年～2030年）
世界の悪性胸膜中皮腫市場セグメント：流通チャネル別
- 世界の悪性胸膜中皮腫の市場：流通チャネル別、概要
- 世界の悪性胸膜中皮腫市場の魅力指数：流通チャネル別
- 世界の悪性胸膜中皮腫の市場規模：病院薬局（2020年～2030年）
- 世界の悪性胸膜中皮腫の市場規模：小売薬局、オンライン薬局（2020年～2030年）

第4章悪性胸膜中皮腫市場、地域分析

調査の地域範囲
地域のスナップショット

第5章南北アメリカの悪性胸膜中皮腫市場：実績と予測

南北アメリカの悪性胸膜中皮腫市場：スナップショット
南北アメリカの悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
南北アメリカの悪性胸膜中皮腫市場：主な要因
南北アメリカの悪性胸膜中皮腫市場：セグメント分析
南北アメリカの悪性胸膜中皮腫市場セグメント：薬剤タイプ別
南北アメリカの悪性胸膜中皮腫市場セグメント：投与経路別
南北アメリカの悪性胸膜中皮腫市場セグメント：流通チャネル別
南北アメリカの悪性胸膜中皮腫市場セグメント：国別
- 南北アメリカの悪性胸膜中皮腫市場：国別、概要
- 米国の悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
- カナダの悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
- その他の南北アメリカの悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）

第6章欧州の悪性胸膜中皮腫市場：実績と予測

欧州の悪性胸膜中皮腫市場：スナップショット
欧州の悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
欧州の悪性胸膜中皮腫市場：主な要因
欧州の悪性胸膜中皮腫市場：セグメント分析
欧州の悪性胸膜中皮腫市場セグメント：薬剤タイプ別
欧州の悪性胸膜中皮腫市場セグメント：投与経路別
欧州の悪性胸膜中皮腫市場セグメント：流通チャネル別
欧州の悪性胸膜中皮腫市場セグメント：国別
- 欧州の悪性胸膜中皮腫市場：国別、概要
- 英国の悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
- ドイツの悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
- フランスの悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
- イタリアの悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
- スペインの悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
- その他の欧州の悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）

第7章アジア太平洋の悪性胸膜中皮腫市場：実績と予測

アジア太平洋の悪性胸膜中皮腫市場：概要
アジア太平洋の悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
アジア太平洋の悪性胸膜中皮腫市場：主な要因
アジア太平洋の悪性胸膜中皮腫市場：セグメント分析
アジア太平洋の悪性胸膜中皮腫市場セグメント：薬剤タイプ別
アジア太平洋の悪性胸膜中皮腫市場セグメント：投与経路別
アジア太平洋の悪性胸膜中皮腫市場セグメント：流通チャネル別
アジア太平洋の悪性胸膜中皮腫市場セグメント：国別
- アジア太平洋の悪性胸膜中皮腫市場：国別、概要
- 中国の悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
- インドの悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
- 日本の悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
- その他のアジア太平洋の悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）

第8章中東・アフリカの悪性胸膜中皮腫市場：実績と予測

中東・アフリカの悪性胸膜中皮腫市場：スナップショット
中東・アフリカの悪性胸膜中皮腫市場：市場規模とCAGR（2020年～2030年）
中東・アフリカの悪性胸膜中皮腫市場：主な要因
中東・アフリカの悪性胸膜中皮腫市場：セグメント分析
中東・アフリカの悪性胸膜中皮腫市場セグメント：薬剤タイプ別
中東・アフリカの悪性胸膜中皮腫市場セグメント：投与経路別
中東・アフリカの悪性胸膜中皮腫市場セグメント：流通チャネル別

第9章市場力学

悪性胸膜中皮腫市場に対する市場力学の影響の評価
促進要因
抑制要因
動向

第10章産業エコシステム分析

ポーター分析

第11章競合ポジショニング

企業の製品ポジショニング
市場ポジションマトリクス
悪性胸膜中皮腫市場の市場シェア分析
企業プロファイル
- Bristol Myers Squibb
- F. Hoffmann-La Roche AG
- Merck & Co., Inc
- Eli Lily & Co.
- Pfizer
- Novartis
- Teva Pharmaceuticals
- GSK plc
- AstraZeneca PLC
- Bayer AG

第12章当社について、免責事項

図表

List of Figures

Figure 1: Global Prevalence and Incidence of Mesothelioma 2018-2021
Figure 2: Global Malignant Pleural Mesothelioma Market Size, By Value, 2020-2023 (USD Million)
Figure 3: Global Malignant Pleural Mesothelioma Market Size, By Value, 2024-2030 (USD Million)
Figure 4: Global Malignant Pleural Mesothelioma Market Share, By Distribution Channel, 2023 (%)
Figure 5: Market Attractiveness Analysis of Malignant Pleural Mesothelioma Market, By Drug Type (2025-2030)
Figure 6: Global Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Millions & CAGR)
Figure 7: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Pemetrexed and Combination , 2020-2030 (USD Million)
Figure 8: Global Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 9: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Cisplatin, 2020-2030 (USD Million)
Figure 10: Global Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 11: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Carboplatin, 2020-2030 (USD Million)
Figure 12: Global Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 13: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Gemcitabine, 2020-2030 (USD Million)
Figure 14: Global Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 15: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Vinorelbine, 2020-2030 (USD Million)
Figure 16: Global Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 17: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Other Drug Types, 2020-2030 (USD Million)
Figure 18: Market Attractiveness Analysis of Malignant Pleural Mesothelioma Market, By Route of Administration (2025-2030)
Figure 19: Global Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 20: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Oral, 2020-2030 (USD Million)
Figure 21: Global Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 22: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Parenteral, 2020-2030 (USD Million)
Figure 23: Market Attractiveness Analysis of Malignant Pleural Mesothelioma Market, By Distribution Channel (2025-2030)
Figure 24: Global Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 25: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Hospital Pharmacy, 2020-2030 (USD Million)
Figure 26: Global Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 27: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Retail & Online Pharmacy, 2020-2030 (USD Million)
Figure 28: Americas Malignant Pleural Mesothelioma Market Size, By Value, 2020H-2030F (USD Million)
Figure 29: Americas Malignant Pleural Mesothelioma Market Share, By Distribution Channel, 2023 (%)
Figure 30: Americas Malignant Pleural Mesothelioma Market, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Millions & CAGR)
Figure 31: Americas Malignant Pleural Mesothelioma Market, By Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 32: Americas Malignant Pleural Mesothelioma Market, By Carboplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 33: Americas Malignant Pleural Mesothelioma Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 34: Americas Malignant Pleural Mesothelioma Market, By Vinorelbine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 35: Americas Malignant Pleural Mesothelioma Market, By Other Drug Types, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 36: Americas Malignant Pleural Mesothelioma Market, By Oral, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 37: Americas Malignant Pleural Mesothelioma Market, By Parenteral, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 38: Americas Malignant Pleural Mesothelioma Market, By Hospital Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 39: Americas Malignant Pleural Mesothelioma Market, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 40: United States Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 41: United States Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 42: United States Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 43: United States Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 44: United States Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 45: Canada Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 46: Canada Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 47: Canada Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 48: Canada Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 49: Canada Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 50: Rest of Americas Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 51: Rest of Americas Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 52: Rest of Americas Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 53: Rest of Americas Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 54: Rest of Americas Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 55: Europe Malignant Pleural Mesothelioma Market Size, By Value, 2020H-2030F (USD Million)
Figure 56: Europe Malignant Pleural Mesothelioma Market Share, By Distribution Channel, 2023 (%)
Figure 57: Europe Malignant Pleural Mesothelioma Market, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Millions & CAGR)
Figure 58: Europe Malignant Pleural Mesothelioma Market, By Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 59: Europe Malignant Pleural Mesothelioma Market, By Carboplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 60: Europe Malignant Pleural Mesothelioma Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 61: Europe Malignant Pleural Mesothelioma Market, By Vinorelbine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 62: Europe Malignant Pleural Mesothelioma Market, By Other Drug Types, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 63: Europe Malignant Pleural Mesothelioma Market, By Oral, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 64: Europe Malignant Pleural Mesothelioma Market, By Parenteral, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 65: Europe Malignant Pleural Mesothelioma Market, By Hospital Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 66: Europe Malignant Pleural Mesothelioma Market, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 67: United Kingdom Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 68: United Kingdom Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 69: United Kingdom Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 70: United Kingdom Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 71: United Kingdom Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 72: Germany Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 73: Germany Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 74: Germany Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 75: Germany Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 76: Germany Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 77: France Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 78: France Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 79: France Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 80: France Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 81: France Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 82: Italy Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 83: Italy Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 84: Italy Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 85: Italy Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 86: Italy Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 87: Spain Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 88: Spain Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 89: Spain Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 90: Spain Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 91: Spain Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 92: Rest of Europe Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 93: Rest of Europe Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 94: Rest of Europe Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 95: Rest of Europe Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 96: Rest of Europe Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 97: Asia Pacific Malignant Pleural Mesothelioma Market Size, By Value, 2020H-2030F (USD Million)
Figure 98: Asia Pacific Malignant Pleural Mesothelioma Market Share, By Distribution Channel, 2023 (%)
Figure 99: Asia Pacific Malignant Pleural Mesothelioma Market, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Millions & CAGR)
Figure 100: Asia Pacific Malignant Pleural Mesothelioma Market, By Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 101: Asia Pacific Malignant Pleural Mesothelioma Market, By Carboplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 102: Asia Pacific Malignant Pleural Mesothelioma Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 103: Asia Pacific Malignant Pleural Mesothelioma Market, By Vinorelbine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 104: Asia Pacific Malignant Pleural Mesothelioma Market, By Other Drug Types, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 105: Asia Pacific Malignant Pleural Mesothelioma Market, By Oral, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 106: Asia Pacific Malignant Pleural Mesothelioma Market, By Parenteral, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 107: Asia Pacific Malignant Pleural Mesothelioma Market, By Hospital Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 108: Asia Pacific Malignant Pleural Mesothelioma Market, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 109: China Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 110: China Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 111: China Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 112: China Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 113: China Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 114: India Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 115: India Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 116: India Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 117: India Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 118: India Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 119: Japan Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 120: Japan Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 121: Japan Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 122: Japan Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 123: Japan Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 124: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 125: Rest of Asia Pacific Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
Figure 126: Rest of Asia Pacific Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
Figure 127: Rest of Asia Pacific Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
Figure 128: Rest of Asia Pacific Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
Figure 129: Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Value, 2020H-2030F (USD Million)
Figure 130: Middle East and Africa Malignant Pleural Mesothelioma Market Share, By Distribution Channel, 2023 (%)
Figure 131: Middle East and Africa Malignant Pleural Mesothelioma Market, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Millions & CAGR)
Figure 132: Middle East and Africa Malignant Pleural Mesothelioma Market, By Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 133: Middle East and Africa Malignant Pleural Mesothelioma Market, By Carboplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 134: Middle East and Africa Malignant Pleural Mesothelioma Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 135: Middle East and Africa Malignant Pleural Mesothelioma Market, By Vinorelbine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 136: Middle East and Africa Malignant Pleural Mesothelioma Market, By Other Drug Types, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 137: Middle East and Africa Malignant Pleural Mesothelioma Market, By Oral, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 138: Middle East and Africa Malignant Pleural Mesothelioma Market, By Parenteral, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 139: Middle East and Africa Malignant Pleural Mesothelioma Market, By Hospital Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 140: Middle East and Africa Malignant Pleural Mesothelioma Market, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 141: Market Share of Prominent Companies of Malignant Pleural Mesothelioma Market, 2023 (%)
Figure 142: Bristol Myers Squibb Revenues, 2021-2023 (USD Million)
Figure 143: Bristol Myers Squibb Revenues, By Geographic Segments, 2023 (%)
Figure 144: Bristol Myers Squibb Revenue , By Products, 2023 (%)
Figure 145: Roche Revenues, 2021-2023 (USD Million)
Figure 146: Roche Revenue , By Sales Division, 2023 (%)
Figure 147: Roche Revenue , By Geographical Segment, 2023 (%)
Figure 148: Merck & Co., Inc. Revenues, 2021-2023 (USD Million)
Figure 149: Merck & Co., Inc. Revenues, By Geographic Segments, 2023 (%)
Figure 150: Merck & Co., Inc. Revenue , By Business Segments, 2023 (%)
Figure 151: Eli Lily & Co. Revenues, 2021-2023 (USD Million)
Figure 152: Eli Lily & Co. Revenues, By Geographic Segments, 2023 (%)
Figure 153: Eli Lily & Co. Revenue , By Business Segments, 2023 (%)
Figure 154: Pfizer Revenues, 2020-2022 (USD Million)
Figure 155: Pfizer Revenues, By Business Segments, 2023 (%)
Figure 156: Pfizer Inc. Revenue , By Geographical Segments, 2023 (%)
Figure 157: Novartis Revenues, 2021-2023 (USD Million)
Figure 158: Novartis Revenues, By Geographic Segments, 2023 (%)
Figure 159: Novartis Revenue , By Business Segments, 2023 (%)
Figure 160: Teva Pharmaceuticals Revenues, 2021-2023 (USD Million)
Figure 161: Teva Pharmaceuticals Revenue , By Geographical Segments, 2023 (%)
Figure 162: GSK PLC Revenue, 2021-2023 (USD Million)
Figure 163: GSK PLC Revenue , By Business Segments, 2023 (%)
Figure 164: GSK PLC Revenue, By Geography Segment, 2023 (%)
Figure 165: AstraZeneca PLC Revenues, 2021-2023 (USD Million)
Figure 166: AstraZeneca PLC Revenues, By Geographic Segments, 2023 (%)
Figure 167: AstraZeneca PLC Revenue , By Business Segments, 2023 (%)
Figure 168: Bayer AG Revenues 2021-2023(USD Million)
Figure 169: Bayer AG Revenues, By Geographic Segments, 2023 (%)
Figure 170: Bayer AG Revenues, By Business Segments, 2023 (%)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: Top exporters of Asbestos by country in 2021
Table A3: Top Importer of Asbestos by country in 2021
Table A4: United States Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A5: United States Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A6: United States Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A7: United States Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A8: United States Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A9: United States Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A10: Canada Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A11: Canada Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A12: Canada Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A13: Canada Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A14: Canada Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A15: Canada Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A16: Rest of Americas Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A17: Rest of Americas Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A18: Rest of Americas Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A19: Rest of Americas Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A20: Rest of Americas Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A21: Rest of Americas Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A22: United Kingdom Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A23: United Kingdom Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A24: United Kingdom Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A25: United Kingdom Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A26: United Kingdom Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A27: United Kingdom Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A28: Germany Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A29: Germany Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A30: Germany Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A31: Germany Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A32: Germany Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A33: Germany Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A34: France Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A35: France Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A36: France Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A37: France Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A38: France Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A39: France Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A40: Italy Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A41: Italy Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A42: Italy Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A43: Italy Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A44: Italy Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A45: Italy Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A46: Spain Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A47: Spain Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A48: Spain Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A49: Spain Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A50: Spain Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A51: Spain Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A52: Rest of Europe Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A53: Rest of Europe Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A54: Rest of Europe Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A55: Rest of Europe Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A56: Rest of Europe Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A57: Rest of Europe Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A58: China Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A59: China Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A60: China Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A61: China Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A62: China Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A63: China Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A64: India Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A65: India Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A66: India Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A67: India Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A68: India Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A69: India Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A70: Japan Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A71: Japan Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A72: Japan Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A73: Japan Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A74: Japan Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A75: Japan Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A76: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
Table A77: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
Table A78: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
Table A79: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
Table A80: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
Table A81: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
Table A82: Bristol Myers Squibb Key Financials, 2021-2023
Table A83: Roche Key Financials, 2021-2023
Table A84: Merck & Co., Inc. Key Financials, 2021-2023
Table A85: Eli Lily & Co. Key Financials, 2021-2023
Table A86: Pfizer Key Financials, 2021-2023
Table A87: Novartis Key Financials, 2021-2023
Table A88: Teva Pharmaceuticals Key Financials, 2021-2023
Table A89: GSK PLC Key Financials, 2020-2022
Table A90: AstraZeneca PLC Key Financials, 2021-2023
Table A91: Bayer AG Key Financials, 2021-2023

Executive Summary

Azoth Analytics has released a research report titled "Global Malignant Pleural Mesothelioma Market (2024 Edition)" which provides a Pemetrexed and Combination analysis of the Global Malignant Pleural Mesothelioma industry in terms of market segmentation By Drug Type (Pemetrexed and Combination, Cisplatin), By Route of Administration (Oral, Parenteral) By Distribution Channel (Hospital Pharmacy, Retail & Online Pharmacy) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.

The report analyses the Malignant Pleural Mesothelioma Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India). The Global Malignant Pleural Mesothelioma market showcased growth at a CAGR of 4.98% during 2020-2023. The market was valued at USD 648.99 Million in 2023 which is expected to reach USD 1045.69 Million in 2030.

The global Malignant Pleural Mesothelioma market is projected to experience significant growth during the forecast period, driven by several key factors. Among the most prominent drivers is the increasing incidence of asbestos-related diseases, particularly in regions with historical asbestos use. According to the World Health Organization (WHO), asbestos remains the primary cause of mesothelioma, underscoring the persistent risk in certain regions.

Innovative treatment options, such as immunotherapy and gene therapy, are also contributing to market expansion by offering improved outcomes and new hope for patients. These novel therapies are gaining traction, especially in developed regions, where advanced healthcare infrastructure supports the adoption of cutting-edge treatments. Rising awareness campaigns are helping improve early detection rates, further enhancing the effectiveness of these therapies.

Furthermore, the growing healthcare infrastructure in emerging markets is enabling greater access to advanced diagnostic and treatment options, fueling market growth.

Scope of the Report:

The report analyses the Malignant Pleural Mesothelioma Market by Value (USD Million).
The report analyses the Malignant Pleural Mesothelioma Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).
The report presents the analysis of Malignant Pleural Mesothelioma Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
The report analyses the Malignant Pleural Mesothelioma Market By Drug Type (Pemetrexed and Combination, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Other Drug Types)
The report analyses the Malignant Pleural Mesothelioma Market By Route of Administration (Oral, and Parenteral).
The report analyses the Malignant Pleural Mesothelioma Market By Distribution Channel (Hospital Pharmacy, Retail & Online Pharmacy).
The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Drug Type, By Route of Administration and By Distribution Channel.
Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analyzed in the report include Bristol Myers Squibb, F. Hoffmann-La Roche AG, Merck & Co., Inc, Eli Lily & Co., Pfizer, Novartis, Teva Pharmaceuticals, GSK plc, AstraZeneca PLC, and Bayer AG

1. Market Background

1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology

2. Analyst Recommendations

2.1 Expanding Clinical Trials for Novel Route of Administration
2.2 Capitalizing on Emerging Markets in Asia-Pacific and Latin America

3. Global Malignant Pleural Mesothelioma Market: Historic and Forecast

3.1 Impact Analysis of Macro Economic Factors on Malignant Pleural Mesothelioma Market
3.2 Top exporters of Asbestos by country in 2021
3.3 Top Importer of Asbestos by country in 2021
3.4 Prevalence and Incidence of Mesothelioma 2018-2021
3.5 Global Malignant Pleural Mesothelioma Market: Dashboard
3.6 Global Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
3.7 Global Malignant Pleural Mesothelioma Market: Market Value Assessment
3.8 Global Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
- 3.8.1 Global Malignant Pleural Mesothelioma Market, By Drug Type Overview
- 3.8.2 Global Malignant Pleural Mesothelioma Market Attractiveness Index, By Drug Type
- 3.8.3 Global Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
- 3.8.4 Global Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
- 3.8.5 Global Malignant Pleural Mesothelioma Market Size, By Carboplatin , By Value, 2020H-2030F (USD Million & CAGR)
- 3.8.6 Global Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
- 3.8.7 Global Malignant Pleural Mesothelioma Market Size, By Vinorelbine , By Value, 2020H-2030F (USD Million & CAGR)
- 3.8.8 Global Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
3.9 Global Malignant Pleural Mesothelioma Market Segmentation: By Route of Administration
- 3.9.1 Global Malignant Pleural Mesothelioma Market, By Route of Administration Overview
- 3.9.2 Global Malignant Pleural Mesothelioma Market Attractiveness Index, By Route of Administration
- 3.9.3 Global Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
- 3.9.4 Global Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
3.10 Global Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
- 3.10.1 Global Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
- 3.10.2 Global Malignant Pleural Mesothelioma Market Attractiveness Index, By Distribution Channel
- 3.10.3 Global Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
- 3.10.4 Global Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)

4. Malignant Pleural Mesothelioma Market, Region Analysis

4.1 Regional Coverage of the Study
4.2 Regional Snapshot

5. Americas Malignant Pleural Mesothelioma Market: Historic and Forecast

5.1 Americas Malignant Pleural Mesothelioma Market: Snapshot
5.2 Americas Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.3 Americas Malignant Pleural Mesothelioma Market: Key Factors
5.4 Americas Malignant Pleural Mesothelioma Market: Segment Analysis
5.5 Americas Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
- 5.5.1 Americas Malignant Pleural Mesothelioma Market, By Drug Type Overview
- 5.5.2 Americas Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
- 5.5.3 Americas Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
- 5.5.4 Americas Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Million & CAGR)
- 5.5.5 Americas Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
- 5.5.6 Americas Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Million & CAGR)
- 5.5.7 Americas Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
5.6 Americas Malignant Pleural Mesothelioma Market Segmentation: Route of Administration
- 5.6.1 Americas Malignant Pleural Mesothelioma Market, By Route of Administration Overview
- 5.6.2 Americas Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
- 5.6.3 Americas Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
5.7 Americas Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
- 5.7.1 Americas Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
- 5.7.2 Americas Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
- 5.7.3 Americas Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
5.8 Americas Malignant Pleural Mesothelioma Market Segmentation: By Country
- 5.8.1 Americas Malignant Pleural Mesothelioma Market, by Country Overview
- 5.8.2 United States Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 5.8.2.1 United States Malignant Pleural Mesothelioma Market, By Drug Type
  - 5.8.2.2 United States Malignant Pleural Mesothelioma Market, By Route of Administration
  - 5.8.2.3 United States Malignant Pleural Mesothelioma Market, By Distribution Channel
- 5.8.3 Canada Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 5.8.3.1 Canada Malignant Pleural Mesothelioma Market, By Drug Type
  - 5.8.3.2 Canada Malignant Pleural Mesothelioma Market, By Route of Administration
  - 5.8.3.3 Canada Malignant Pleural Mesothelioma Market, By Distribution Channel
- 5.8.4 Rest of Americas Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 5.8.4.1 Rest of Americas Malignant Pleural Mesothelioma Market, By Drug Type
  - 5.8.4.2 Rest of Americas Malignant Pleural Mesothelioma Market, By Route of Administration
  - 5.8.4.3 Rest of Americas Malignant Pleural Mesothelioma Market, By Distribution Channel

6. Europe Malignant Pleural Mesothelioma Market: Historic and Forecast

6.1 Europe Malignant Pleural Mesothelioma Market: Snapshot
6.2 Europe Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.3 Europe Malignant Pleural Mesothelioma Market: Key Factors
6.4 Europe Malignant Pleural Mesothelioma Market: Segment Analysis
6.5 Europe Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
- 6.5.1 Europe Malignant Pleural Mesothelioma Market, By Drug Type Overview
- 6.5.2 Europe Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
- 6.5.3 Europe Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
- 6.5.4 Europe Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Million & CAGR)
- 6.5.5 Europe Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
- 6.5.6 Europe Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Million & CAGR)
- 6.5.7 Europe Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
6.6 Europe Malignant Pleural Mesothelioma Market Segmentation: By Route of Administration
- 6.6.1 Europe Malignant Pleural Mesothelioma Market, By Route of Administration Overview
- 6.6.2 Europe Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
- 6.6.3 Europe Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
6.7 Europe Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
- 6.7.1 Europe Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
- 6.7.2 Europe Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
- 6.7.3 Europe Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
6.8 Europe Malignant Pleural Mesothelioma Market Segmentation: By Country
- 6.8.1 Europe Malignant Pleural Mesothelioma Market, by Country Overview
- 6.8.2 United Kingdom Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 6.8.2.1 United Kingdom Malignant Pleural Mesothelioma Market, By Drug Type
  - 6.8.2.2 United Kingdom Malignant Pleural Mesothelioma Market, By Route of Administration
  - 6.8.2.3 United Kingdom Malignant Pleural Mesothelioma Market, By Distribution Channel
- 6.8.3 Germany Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 6.8.3.1 Germany Malignant Pleural Mesothelioma Market, By Drug Type
  - 6.8.3.2 Germany Malignant Pleural Mesothelioma Market, By Route of Administration
  - 6.8.3.3 Germany Malignant Pleural Mesothelioma Market, By Distribution Channel
- 6.8.4 France Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 6.8.4.1 France Malignant Pleural Mesothelioma Market, By Drug Type
  - 6.8.4.2 France Malignant Pleural Mesothelioma Market, By Route of Administration
  - 6.8.4.3 France Malignant Pleural Mesothelioma Market, By Distribution Channel
- 6.8.5 Italy Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 6.8.5.1 Italy Malignant Pleural Mesothelioma Market, By Drug Type
  - 6.8.5.2 Italy Malignant Pleural Mesothelioma Market, By Route of Administration
  - 6.8.5.3 Italy Malignant Pleural Mesothelioma Market, By Distribution Channel
- 6.8.6 Spain Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 6.8.6.1 Spain Malignant Pleural Mesothelioma Market, By Drug Type
  - 6.8.6.2 Spain Malignant Pleural Mesothelioma Market, By Route of Administration
  - 6.8.6.3 Spain Malignant Pleural Mesothelioma Market, By Distribution Channel
- 6.8.7 Rest of Europe Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 6.8.7.1 Rest of Europe Malignant Pleural Mesothelioma Market, By Drug Type
  - 6.8.7.2 Rest of Europe Malignant Pleural Mesothelioma Market, By Route of Administration
  - 6.8.7.3 Rest of Europe Malignant Pleural Mesothelioma Market, By Distribution Channel

7. Asia Pacific Malignant Pleural Mesothelioma Market: Historic and Forecast

7.1 Asia Pacific Malignant Pleural Mesothelioma Market: Snapshot
7.2 Asia Pacific Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.3 Asia Pacific Malignant Pleural Mesothelioma Market: Key Factors
7.4 Asia Pacific Malignant Pleural Mesothelioma Market: Segment Analysis
7.5 Asia Pacific Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
- 7.5.1 Asia Pacific Malignant Pleural Mesothelioma Market, By Drug Type Overview
- 7.5.2 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
- 7.5.3 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
- 7.5.4 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Million & CAGR)
- 7.5.5 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
- 7.5.6 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Million & CAGR)
- 7.5.7 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
7.6 Asia Pacific Malignant Pleural Mesothelioma Market Segmentation: By Route of Administration
- 7.6.1 Asia Pacific Malignant Pleural Mesothelioma Market, By Route of Administration Overview
- 7.6.2 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
- 7.6.3 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
7.7 Asia Pacific Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
- 7.7.1 Asia Pacific Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
- 7.7.2 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
- 7.7.3 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
7.8 Asia Pacific Malignant Pleural Mesothelioma Market Segmentation: By Country
- 7.8.1 Asia Pacific Malignant Pleural Mesothelioma Market, by Country Overview
- 7.8.2 China Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 7.8.2.1 China Malignant Pleural Mesothelioma Market, By Drug Type
  - 7.8.2.2 China Malignant Pleural Mesothelioma Market, By Route of Administration
  - 7.8.2.3 China Malignant Pleural Mesothelioma Market, By Distribution Channel
- 7.8.3 India Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 7.8.3.1 India Malignant Pleural Mesothelioma Market, By Drug Type
  - 7.8.3.2 India Malignant Pleural Mesothelioma Market, By Route of Administration
  - 7.8.3.3 India Malignant Pleural Mesothelioma Market, By Distribution Channel
- 7.8.4 Japan Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 7.8.4.1 Japan Malignant Pleural Mesothelioma Market, By Drug Type
  - 7.8.4.2 Japan Malignant Pleural Mesothelioma Market, By Route of Administration
  - 7.8.4.3 Japan Malignant Pleural Mesothelioma Market, By Distribution Channel
- 7.8.5 Rest of Asia Pacific Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  - 7.8.5.1 Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Drug Type
  - 7.8.5.2 Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Route of Administration
  - 7.8.5.3 Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Distribution Channel

8. Middle East and Africa Malignant Pleural Mesothelioma Market: Historic and Forecast

8.1 Middle East and Africa Malignant Pleural Mesothelioma Market: Snapshot
8.2 Middle East and Africa Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
8.3 Middle East and Africa Malignant Pleural Mesothelioma Market: Key Factors
8.4 Middle East and Africa Malignant Pleural Mesothelioma Market: Segment Analysis
8.5 Middle East and Africa Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
- 8.5.1 Middle East and Africa Malignant Pleural Mesothelioma Market, By Drug Type Overview
- 8.5.2 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
- 8.5.3 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
- 8.5.4 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Million & CAGR)
- 8.5.5 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
- 8.5.6 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Million & CAGR)
- 8.5.7 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
8.6 Middle East and Africa Malignant Pleural Mesothelioma Market Segmentation: By Route of Administration
- 8.6.1 Middle East and Africa Malignant Pleural Mesothelioma Market, By Route of Administration Overview
- 8.6.2 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
- 8.6.3 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
8.7 Middle East and Africa Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
- 8.7.1 Middle East and Africa Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
- 8.7.2 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
- 8.7.3 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)

9. Market Dynamics

9.1 Impact assessment of Market Dynamics on Malignant Pleural Mesothelioma Market
9.2 Drivers
9.3 Restraints
9.4 Trends

10. Industry Ecosystem Analysis

10.1 Porter Analysis

11. Competitive Positioning

11.1 Companies' Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of Malignant Pleural Mesothelioma Market
11.4 Company Profiles
- 11.4.1 Bristol Myers Squibb
- 11.4.2 F. Hoffmann-La Roche AG
- 11.4.3 Merck & Co., Inc
- 11.4.4 Eli Lily & Co.
- 11.4.5 Pfizer
- 11.4.6 Novartis
- 11.4.7 Teva Pharmaceuticals
- 11.4.8 GSK plc
- 11.4.9 AstraZeneca PLC
- 11.4.10 Bayer AG

悪性胸膜中皮腫の世界市場：薬剤タイプ別、投与経路別、流通経路別、地域別、国別の分析、市場考察、予測

Global Malignant Pleural Mesothelioma Market : Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast

目次

第1章市場背景

第2章アナリストの推奨事項

第3章世界の悪性胸膜中皮腫市場：実績と予測

第4章悪性胸膜中皮腫市場、地域分析

第5章南北アメリカの悪性胸膜中皮腫市場：実績と予測

第6章欧州の悪性胸膜中皮腫市場：実績と予測

第7章アジア太平洋の悪性胸膜中皮腫市場：実績と予測

第8章中東・アフリカの悪性胸膜中皮腫市場：実績と予測

第9章市場力学

第10章産業エコシステム分析

第11章競合ポジショニング

第12章当社について、免責事項

List of Figures

List of Tables

Executive Summary

Table of Contents

1. Market Background

2. Analyst Recommendations

3. Global Malignant Pleural Mesothelioma Market: Historic and Forecast

4. Malignant Pleural Mesothelioma Market, Region Analysis

5. Americas Malignant Pleural Mesothelioma Market: Historic and Forecast

6. Europe Malignant Pleural Mesothelioma Market: Historic and Forecast

7. Asia Pacific Malignant Pleural Mesothelioma Market: Historic and Forecast

8. Middle East and Africa Malignant Pleural Mesothelioma Market: Historic and Forecast

9. Market Dynamics

10. Industry Ecosystem Analysis

11. Competitive Positioning

12. About Us & Disclaimer

悪性胸膜中皮腫の世界市場：薬剤タイプ別、投与経路別、流通経路別、地域別、国別の分析、市場考察、予測

Global Malignant Pleural Mesothelioma Market : Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast

目次

第1章 市場背景

第2章 アナリストの推奨事項

第3章 世界の悪性胸膜中皮腫市場：実績と予測

第4章 悪性胸膜中皮腫市場、地域分析

第5章 南北アメリカの悪性胸膜中皮腫市場：実績と予測

第6章 欧州の悪性胸膜中皮腫市場：実績と予測

第7章 アジア太平洋の悪性胸膜中皮腫市場：実績と予測

第8章 中東・アフリカの悪性胸膜中皮腫市場：実績と予測

第9章 市場力学

第10章 産業エコシステム分析

第11章 競合ポジショニング

第12章 当社について、免責事項

List of Figures

List of Tables

Executive Summary

Table of Contents

1. Market Background

2. Analyst Recommendations

3. Global Malignant Pleural Mesothelioma Market: Historic and Forecast

4. Malignant Pleural Mesothelioma Market, Region Analysis

5. Americas Malignant Pleural Mesothelioma Market: Historic and Forecast

6. Europe Malignant Pleural Mesothelioma Market: Historic and Forecast

7. Asia Pacific Malignant Pleural Mesothelioma Market: Historic and Forecast

8. Middle East and Africa Malignant Pleural Mesothelioma Market: Historic and Forecast

9. Market Dynamics

10. Industry Ecosystem Analysis

11. Competitive Positioning

12. About Us & Disclaimer

第1章市場背景

第2章アナリストの推奨事項

第3章世界の悪性胸膜中皮腫市場：実績と予測

第4章悪性胸膜中皮腫市場、地域分析

第5章南北アメリカの悪性胸膜中皮腫市場：実績と予測

第6章欧州の悪性胸膜中皮腫市場：実績と予測

第7章アジア太平洋の悪性胸膜中皮腫市場：実績と予測

第8章中東・アフリカの悪性胸膜中皮腫市場：実績と予測

第9章市場力学

第10章産業エコシステム分析

第11章競合ポジショニング

第12章当社について、免責事項